National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
The present study was aimed at evaluation of antiprogesterone and PGF2αtherapy either alone or in combination for the treatment of canine pyometra. A total of twenty-three female dogs suffering from open pyometra were divided in three groups based on type of treatment viz. Group I (n = 8; PGF2α), Group II (n= 7; Mifepristone) and Group III (n = 8; PGF2α + Mifepristone). Group I dogs were administered with PGF2α @ 0.1 mg/kg b.wt. bid subcutaneously for 5 days. Group II dogs received Mifepristone @ 2.5 mg/kg b.wt. orally for 5 days. Group III dogs were given combination of Mifepristone @ 2.5 mg/kg bid orally upto 5 days and PGF2αsubcutaneously @ 0.2 mg/kg b.wt. on alternate days i.e. days 1, 3 and 5. The animals from all the groups were administered with Enrofloxacin @ 5 mg/kg b.wt. bid intramuscularly for 5 days alongwith supportive therapy. Prior to treatment vaginal swab (for microbial assay) from all animals were taken. All the animals were subjected to hematobiochemical parameters and ultrasonography pre and post treatment. Microbial assay of vaginal swab revealed predominance of Escherichia coli (65.21%) followed by Staphylococcus sp. (21.74%), Klebsiella sp. (8.70%)and Pseudomonas sp. (4.34%). Following treatment there was significant decrease (P<0.05) in TLC and neutrophil percent in all the groups. Post treatment ultrasonography showed significant decrease (P<0.05) in uterine diameter following therapy in all the groups. The success rate in terms of cessation of discharge and disappearance of clinical signs (viz.vomition, anorexia, polydipsia, polyurea) of Group I, Group II and Group III was 87.5%, 100% and 87.5% respectively. It was concluded that antiprogesterone therapy was most effective for the treatment of canine pyometra followed by PGF2α alone and combination of PGF2α and antiprogesterone therapy.
Citations |
 |
 |
 |
 |
